ANI Pharmaceuticals, Inc. Overview
Pro stress-test →ANI Pharmaceuticals is a diversified biopharmaceutical company developing, manufacturing, and commercializing innovative therapeutics through three segments: a Rare Disease business focusing on ophthalmology, rheumatology, nephrology, neurology, and pulmonology; a Generics business leveraging U.S.-based manufacturing; and a Brands business. The company reported full-year 2025 sales of $883.4 million and reaffirmed 2026 revenue guidance of $1.06-$1.12 billion, underpinned by strong rare disease and generics performance.
Strategic Profile
Pro stress-test →ANI is accelerating its transformation into a leading Rare Disease company in 2026, supported by strong execution in Generics and disciplined capital deployment. Cortrophin Gel, the company's lead rare disease asset, delivered 2025 net revenues of $347.8 million, up 76% year-over-year, with rare disease projected to represent approximately 60% of total 2026 net revenues.
Competitive Landscape
Pro stress-test →ANI specializes in developing and commercializing innovative therapeutics, focusing on rare diseases, generics, and branded products. The company competes in specialized rare disease markets with differentiated assets like Cortrophin Gel (ophthalmology/rheumatology indications) and ILUVIEN, while maintaining a generics portfolio to offset future branded pressure.
Industry Context
ANI Pharmaceuticals, Inc. operates in Biopharmaceuticals - Specialty/Rare Disease and Generics.
Key facts
Headquarters: Princeton, New Jersey, USA · Revenue: $883.4M (2025 actual); $1.06-$1.12B (2026 guidance)